Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.

Abstract

Although not yet licensed for this use, rituximab is currently used to treat severe, refractory systemic autoimmune diseases, with the most favourable results being observed in Sjögren's syndrome, inflammatory myopathies, systemic lupus erythematosus and cryoglobulinemia.